BRAF V600E-mutant mCRC

Image
Top banner braf

The first and only treatment approved specifically for patients with BRAF V600E-mutant mCRC, who have received prior systemic therapy1,2

BRAFV600E-mutant mCRC
is an area of high unmet need

Patients with BRAFV600E-mutant mCRC have a poor prognosis2,3

  • Overall survival is dramatically lower than for those with BRAF wild-type disease4
  • Patients with BRAFV600E-mutant mCRC demonstrate a limited response to conventional chemotherapy-based regimens2

Mutations are common
in patients with mCRC2,5

8-0%
of patients with mCRC have BRAF mutationa
BRAF mutation is
a predictive marker
Overall survival is dramatically lower than for those with BRAF wild-type disease

 

Image
ESMO-guidelines.PNG

aThe V600E mutation accounts for approximately 95% of the activating mutations in BRAF in mCRC.6
ESMO, European Society for Medical Oncology.

 

HealthCare Professionals​

This is an international website for BRAFTOVI dedicated to Healthcare professionals ​​

IMPORTANT: the information on this website is based on the European Summary of Product Characteristics. Prescribing Information and indication may vary per country. You must refer to your country prescribing information. Please be aware we do not take responsibility for accessing such information which may not comply with the regulation or usage in your country.

I certify that:

I am Healthcare Professional outside the US and I have read the information above​. 

Patients

This is an international website for BRAFTOVI dedicated to Healthcare professionals.

I am a patient outside the US​